We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

14 hedge funds and large institutions have $32.6M invested in Strongbridge Biopharma plc. in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 15 → 14 (-1)

19% less capital invested

Capital invested by funds: $40M → $32.6M (-$7.41M)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$170K
2
BFA
BlackRock Fund Advisors
California
+$76.5K
3
BIM
BlackRock Investment Management
Delaware
+$2.96K
4
BC
Broadfin Capital
New York
+$5

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$4.51M
2
GTC
Ghost Tree Capital
New York
-$332K
3
SFM
Sphera Funds Management
Israel
-$277K
4
RCM
RA Capital Management
Massachusetts
-$72.5K
5
UBS Group
UBS Group
Switzerland
-$4.21K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$10.6M -$72.5K -15,364 -0.6%
NMC
2
NEA Management Company
Maryland
$8.52M – – –
BC
3
Broadfin Capital
New York
$6.59M +$5 +1 +0%
TAF
4
Tredje AP-fonden
Sweden
$3.62M – – –
GPCM
5
Granite Point Capital Management
Massachusetts
$2.81M +$3.33M +705,480 New
CC
6
Caxton Corporation
New Jersey
$143K +$170K +35,977 New
BA
7
BlackRock Advisors
Delaware
$130K -$3.06K -649 -2%
BFA
8
BlackRock Fund Advisors
California
$64K +$76.5K +16,204 New
Bank of America
9
Bank of America
North Carolina
$12K – – –
UBS Group
10
UBS Group
Switzerland
$8K -$4.21K -892 -30%
BIM
11
BlackRock Investment Management
Delaware
$8K +$2.96K +628 +47%
BJ
12
BlackRock Japan
Japan
$7K -$85 -18 -1%
Manulife (Manufacturers Life Insurance)
13
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K – – –
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$2K -$3.82K -809 -59%
ACP
15
Acuta Capital Partners
California
– -$4.51M -1,063,747 Closed
GTC
16
Ghost Tree Capital
New York
– -$332K -72,726 Closed
SFM
17
Sphera Funds Management
Israel
– -$277K -60,718 Closed

SBBP Hedge Fund Activity: Q2 2016 in Review

14 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2016, worth a combined $32.6M — down 19% from $40M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SBBP and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.

The largest buyer was Caxton Corporation, opening a new position worth an estimated $170K. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $4.51M sold.

  • 14 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2016, down from 15 in Q1 2016.
  • Funds reported $32.6M of Strongbridge Biopharma plc. stock for Q2 2016, down 19% quarter-over-quarter.
  • 3 funds opened new Strongbridge Biopharma plc. positions in Q2 2016 and 4 closed out, a net change of -1 holder.
  • The largest Strongbridge Biopharma plc. buyer in Q2 2016 was Caxton Corporation, an estimated $170K added.
  • The largest Strongbridge Biopharma plc. seller in Q2 2016 was Acuta Capital Partners, an estimated $4.51M sold.

Based on aggregated 13F filings for Q2 2016.